سعر فيريبروكس 500مجم 100 قرص 2024

Deferiprone 500 mg tablets, pack of 100 (Apotex Inc., Canada; Egyptian agent listed as Egyptian Pharmex). Listed in the source as a net-price item.

• Monotherapy for iron overload in thalassaemia major when current chelation therapy is contraindicated or inadequate.European Medicines Agency (EMA)
• In combination with another chelator in thalassaemia major when monotherapy with any iron chelator is ineffective, or when life-threatening consequences of iron overload (mainly cardiac) justify rapid or intensive correction.European Medicines Agency (EMA)

• Very common (10% or more): nausea, vomiting, abdominal pain and chromaturia. Common: neutropenia, agranulocytosis, increased appetite, headache, diarrhoea, arthralgia, fatigue and increased liver enzymes. Frequency not known: hypersensitivity reactions, rash, urticaria.International label, same formulation · European Medicines Agency (EMA)
• Low plasma zinc has occurred in a minority of patients and normalised with oral zinc supplementation; arthropathy ranging from mild joint pain to severe arthritis has been reported.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to deferiprone or any excipient.International label, same formulation · European Medicines Agency (EMA)
• History of recurrent episodes of neutropenia or history of agranulocytosis.International label, same formulation · European Medicines Agency (EMA)
• Pregnancy and breast-feeding.International label, same formulation · European Medicines Agency (EMA)

• Deferiprone can cause neutropenia and agranulocytosis (about 1.1%; fatal cases reported). Do not start in neutropenic patients; interrupt immediately if infection develops and obtain an absolute neutrophil count without delay. Rechallenge after agranulocytosis is contraindicated.International label, same formulation · European Medicines Agency (EMA)
• Neurological disorders have been seen in children at more than 2.5 times the maximum dose and also at standard doses; doses above 100 mg/kg/day are not recommended and treatment should stop if neurological disorders occur.International label, same formulation · European Medicines Agency (EMA)
• Urine may show a reddish-brown discolouration due to excretion of the iron-deferiprone complex.International label, same formulation · European Medicines Agency (EMA)

• Medicines associated with neutropenia or agranulocytosisContraindicated together because the mechanism of deferiprone-induced neutropenia is unknown.European Medicines Agency (EMA)
• Aluminium-based antacidsDeferiprone binds metal cations; concomitant ingestion with aluminium-based antacids is not recommended.European Medicines Agency (EMA)
• Vitamin CNot formally studied; caution is advised when deferiprone and vitamin C are given together (by analogy with a reported deferoxamine-vitamin C interaction).European Medicines Agency (EMA)

• Contraindicated in pregnancy: no adequate human data and reproductive toxicity in animals; pregnant women must stop deferiprone immediately.International label, same formulation · European Medicines Agency (EMA)
• US label: based on animal developmental toxicity, deferiprone can cause fetal harm; human data are insufficient to inform drug-associated risk.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Must not be used by breast-feeding mothers; if treatment is unavoidable, breast-feeding must be stopped.International label, same formulation · European Medicines Agency (EMA)

• Deferiprone: Bidentate ligand that binds iron in a 3:1 (deferiprone:iron) molar ratio, promoting iron excretion (EU SmPC 5.1).